Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Gervas, V. Muradas, E. Bazán, E. Aguado, J. Yébenes (1983)
Effects of 3‐OM‐dopa on monoarnine metabolism in rat brainNeurology, 33
Evans Evans, Triggs Triggs, Broe Broe, Saines Saines (1980)
Systemic availability of orally adminstered L‐dopa in the elderly parkinsonian patientEur J Clin Pharmacol, 17
Fabbrini et al: L-Dopa and Motor Fluctuations in PD 375
E. Melamed, F. Hefti, D. Pettibone, J. Liebman, R. Wurtman (1981)
Aromatic L‐amino acid decarboxylase in rat corpus striatumNeurology, 31
On - off response : clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients
K. Bergmann, J. Limongi, Y. Lowe, M. Mendoza, M. Yahr (1984)
POTENTIATION OF THE "DOPA" EFFECT IN PARKINSONISM BY A DIRECT GABA RECEPTOR AGONISTThe Lancet, 323
J. Nutt, W. Woodward, J. Hammerstad, J. Carter, John Anderson (1984)
The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.The New England journal of medicine, 310 8
D. Chicot, R. Wright, B. Brotman, A. Prince (1975)
HEPANOSTICON IN SCREENING FOR HBsAgThe Lancet, 305
K. Sasahara, T. Nitanai, T. Habara, T. Morioka, E. Nakajima (1980)
Dosage form design for improvement of bioavailability of levodopa III: Influence of dose on pharmacokinetic behavior of levodopa in dogs and Parkinsonian patients.Journal of pharmaceutical sciences, 69 12
Melamed Melamed, Hefti Hefti, Pettibone Pettibone (1981)
Aromatic L‐amino acid decarboxylase in rat corpus striatum: implications for action of L‐dopa in parkinsonismNeurology, 31
E. Melamed, F. Hefti, R. Wurtman (1980)
Nonaminergic striatal neurons convert exogenous l‐dopa to dopamine in parkinsonismAnnals of Neurology, 8
D. Wade, P. Mearrick, D. Birkett, J. Morris (1974)
Variability of L-dopa absorption in man.Australian and New Zealand journal of medicine, 4 2
S. Fahn (1974)
“On‐off” phenomenon with levodopa therapy in parkinsonismNeurology, 24
R. Sweet, F. Mcdowell (1974)
Plasma dopa concentrations and the “on‐off” effect after chronic treatment of Parkinson's diseaseNeurology, 24
Papavasiliou Papavasiliou, McDowell McDowell, Wang Wang (1979)
Plasma dopa and growth hormone in parkinsonism: oscillations in symptomsNeurology, 29
MD Direnfeld, ”. Spero, MD Marotta, MD Seeman (1978)
The L‐dopa on‐off effect in parkinson disease: Treatment by transient drug withdrawal and dopamine receptor resensitizationAnnals of Neurology, 4
L. Wade, R. Katzman (1975)
3-0-Methyldopa uptake and inhibition of L-dopa at the blood-brain barrierLife Sciences, 17
L. Rivera-calimlim, D. Tandon, F. Anderson, R. Joynt (1977)
The clinical picture and plasma levodopa metabolite profile of parkinsonian nonresponders. Treatment with levodopa and decarboxylase inhibitor.Archives of neurology, 34 4
H. Bernheimer, W. Birkmayer, O. Hornykiewicz, K. Jellinger, F. Seitelberger (1973)
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.Journal of the neurological sciences, 20 4
Compensatory biochemical changes at the striatal dopamine synapse in Parkinson ’ s disease : limitations of L - dopa therapy
P. Jenner, M. Sheehy, C. Marsden (1983)
Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease.British journal of clinical pharmacology, 15 Suppl 2
L. Beckman, N. Myrberg (1972)
The incidence of cleft lip and palate in Northern Sweden.Human heredity, 22 5
Wagner Wagner, Vitali Vitali, Palfreyman Palfreyman (1982)
Simultaneous determination of 3,4‐dihydroxyphenylalanine, 5‐hydroxytryptophan, dopamine, 4‐hydroxy‐3‐methoxyphenylalanine, norepinephrine, 3,4‐dihydroxyphenylacetic acid, homovanillic acid, serotonin, and 5‐hydroxyindoleacetic acid in rat cerebrospinal fluid and brain by high‐performance liquid chromatography with electrochemical detectionJ Neurochem, 38
S. Spencer, G. Wooten (1984)
Altered pharmacokinetics of L‐dopa metabolism in rat striatum deprived of dopaminergic innervationNeurology, 34
P. Papavasiliou, F. Mcdowell, Ying Wang, Victoria Rosal, Samuel Miller (1979)
Plasma DOPA and growth hormone in parkinsonismNeurology, 29
C. Clough, K. Bergmann, M. Yahr (1984)
Cholinergic and dopaminergic mechanisms in Parkinson's disease after long-term L-DOPA administration.Advances in neurology, 40
Stable responders. Patients with no cIinicalIy appreciable fluctuations in motor performance while receiving levo-dopa-carbidopa every 4 to 6 hours
A. Reches, S. Fahn (1982)
3‐O‐ methyldopa blocks dopa metabolism in rat corpus striatumAnnals of Neurology, 12
W. Weiner, W. Koller, S. Perlik, P. Nausieda, H. Klawans (1980)
Drug holiday and management of Parkinson diseaseNeurology, 30
M. Hoehn, R. Elton (1985)
Low dosages of bromocriptine added to levodopa in Parkinson's diseaseNeurology, 35
C. Marsden, J. Parkes (1977)
SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASEThe Lancet, 309
P. Teychenné, M. Ziegler, C. Lake, S. Enna (1982)
Low CSF GABA in parkinsonian patients who respond poorly to therapy or suffer from the “on‐off” phenomenonAnnals of Neurology, 11
E. Tolosa, W. Martin, H. Cohen, R. Jacobson (1975)
Patterns of clinical response and plasma dopa levels in Parkinson's diseaseNeurology, 25
B. Djahanguiri, S. Hemmati, D. Sadeghi, A. Firouzabadi (1967)
The prevention of acute gastric ulcer in the rat by alpha-methyldopa.Medicina et pharmacologia experimentalis. International journal of experimental medicine, 17 5
Wade Wade, Mearrick Mearrick, Birkett Birkett, Morris Morris (1974)
Variability of L‐dopa absorption in manAust NZ J Med, 4
Chase Chase, Ng Ng (1972)
O‐Methyldopa in parkinsonismNeurology, 22
J. Wagner, P. Vitali, M. Palfreyman, M. Zraika, Stéphane Huot (1982)
Simultaneous Determination of 3,4‐Dihydroxyphenylalanine, 5‐Hydroxytryptophan, Dopamine, 4‐Hydroxy‐3‐Methoxyphenylalanine, Norepinephrine, 3,4‐Dihydroxyphenylacetic Acid, Homovanillic Acid, Serotonin, and 5‐Hydroxyindoleacetic Acid in Rat Cerebrospinal Fluid and Brain by High‐Performance Liquid ChroJournal of Neurochemistry, 38
M. Rossor, J. Watkins, M. Brown, J. Reid, C. Dollery (1980)
Plasma levodopa, dopamine and therapeutic response following levodopa therapy of Parkinsonian patientsJournal of the Neurological Sciences, 46
A. Granérus (2009)
Factors influencing the occurrence of "on-off" symptoms during long-term treatment with L-dopa.Acta medica Scandinavica, 203 1-2
T. Chase, J. Juncos, C. Serrati, G. Fabbrini, G. Bruno (1987)
Fluctuation in response to chronic levodopa therapy: pathogenetic and therapeutic considerations.Advances in neurology, 45
M. Marion, F. Stocchi, N. Quinn, P. Jenner, C. Marsden (1986)
Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data.Clinical neuropharmacology, 9 2
C. Markham, S. Diamond (1986)
Long‐term follow‐up of early dopa treatment in Parkinson's diseaseAnnals of Neurology, 19
R. Hardie, A. Lees, G. Stern (1984)
On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.Brain : a journal of neurology, 107 ( Pt 2)
H. Doller, J. Connor (1980)
Changes in Neostriatal Dopamine Concentrations in Response to Levodopa InfusionsJournal of Neurochemistry, 34
M. Yahr (1977)
LONG-TERM LEVODOPA IN PARKINSON'S DISEASEThe Lancet, 309
D. Cadwallader (1983)
Biopharmaceutics and Drug Interactions
J. Nutt, W. Woodward, John Anderson (1985)
The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: The mechanism of action in the treatment of parkinsonismAnnals of Neurology, 18
(1981)
LSNLR General Non-Linear Least Squares Regression Program User’s Manual
R. Lesser, S. Fahn, S. Snider, L. Cote, W. Isgreen, R. Barrett (1979)
Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapyNeurology, 29
J. Morgan, J. Bianchine, H. Spiegel, L. Rivera-calimlim, R. Hersey (1971)
Metabolism of levodopa in patients with Parkinson's disease. Radioactive and fluorometric assays.Archives of neurology, 25 1
S. Ogasahara, Y. Nishikawa, Mitsuo Takahashi, K. Wada, Yusaku Nakamura, S. Yorifuji, S. Tarui (1984)
Dopamine metabolism in the central nervous system after discontinuation of l-dopa therapy in patients with Parkinson diseaseJournal of the Neurological Sciences, 66
Rivera‐Calimlim Rivera‐Calimlim, Tandon Tandon, Anderson Anderson, Joynt Joynt (1977)
The clinical picture and plasma levodopa metabolite profile of parkinsonian nonrespondersArch Neurol, 34
R. Blanco, R. Chakraborty (1975)
Genetic distance analysis of twenty-two South American Indian populations.Human heredity, 25 3
Eriksson Eriksson, Magnusson Magnusson, Carlsson Carlsson (1984)
“On‐off” phenomenon in Parkinson's disease: correlation to the concentration of dopa in plasmaJ Neural Transm, 59
K. Shaw, A. Lees, G. Stern (1980)
The impact of treatment with levodopa on Parkinson's disease.The Quarterly journal of medicine, 49 195
N. Quinn, J. Parkes, C. Marsden (1984)
Control of on/off phenomenon by continuous intravenous infusion of levodopaNeurology, 34
H. Doller, J. Connor, D. Lock, R. Sloviter, B. Dvorchik, E. Vesell (1978)
Levodopa pharmacokinetics. Alterations after benserazide, a decarboxylase inhibitor.Drug metabolism and disposition: the biological fate of chemicals, 6 2
C. Marsden, J. Parkes (1976)
"ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPYThe Lancet, 307
R. Kartzinel, D. Calne (1976)
Studies with bromocriptine Part 1. “On‐off” phenomenaNeurology, 26
Morgan Morgan, Bianchine Bianchine, Spiegel Spiegel (1971)
Metabolism of levodopa in patients with Parkinson's diseaseArch Neurol, 25
Tyrone Lee, P. Seeman, A. Rajput, I. Farley, O. Hornykiewicz (1978)
Receptor basis for dopaminergic supersensitivity in Parkinson's diseaseNature, 273
L. Rivera-calimlim, C. Dujovne, J. Morgan, L. Lasagna, J. Bianchine (1970)
L-dopa treatment failure: explanation and correction.British Medical Journal, 4
Hoehn Hoehn, Yahr Yahr (1967)
Parkinsonism: onset, progression and mortalityNeurology, 17
A. Barbeau (1974)
The clinical physiology of side effects in long-term L-DOPA therapy.Advances in neurology, 5
The contribution of the peripheral and central pharmacokinetic mechanisms of levodopa to the pathogenesis of the motor fluctuations that complicate its long‐term administration was studied in 28 parkinsonian patients. The rate of levodopa clearance from the general circulation, its plasma half‐life, and apparent volume of distribution were indistinguishable between patients with the on‐off or the wearing‐off phenomenon and those with a stable response to levodopa or those who had not been previously treated with levodopa. Peripheral pharmacokinetic factors are thus unlikely to account for the development of these response fluctuations. Conversely, the efficacy half‐time of levodopa differed markedly among the four response groups studied and may provide a quantitative index of central mechanisms that favor the development of the wearing‐off and on‐off phemonena. Although symptom duration was the best predictor of the severity of untreated parkinsonism, levodopa dose correlated best with response half‐time. The wearing‐off phenomenon may primarily reflect the loss of buffering capacity caused by degeneration of the dopamine neurons, while the development of the on‐off phenomenon appears to require additional postsynaptic changes, possibly at the receptor level.
Annals of Neurology – Wiley
Published: Apr 1, 1987
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.